SMER28 and Tat‐Beclin decreased proteostat‐positive aggregates in both ALS (37% ± 14 and 62.5% ± 5.5) and isogenic MNs (38% ± 11.7, 66.9% ± 5 for 298G) as compared to SLO‐treated control. The gene discussed is TAT; the disease is amyotrophic lateral sclerosis.